Spectral Medical Provides December Tigris Trial Update
• 140 patients enrolled
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
Tigris Enrollment:
- Strong close to 2024 enrollment with 140 patients enrolled at end of December 2024
- 59 patients enrolled in 2024 vs. 31 patients enrolled in 2023
- Experienced improved enrollment in December as issues related to the production of critical intravenous fluids started to ease
Dr. John Kellum, Chief Medical Officer of Spectral, stated, “We view December as a transitional month from an enrollment perspective, as the medical supply chain issues eased. Given the continued strong engagement and enthusiasm at our Tigris sites, we anticipate a return to a more normalized enrollment rate in the new year.”
“Our enrollment throughout 2024 was incredibly robust – even when taking into account the enrollment disruptions encountered throughout the fourth quarter,” said Chris Seto, Chief Executive Officer of Spectral Medical. “We are very much in the final stretch of Tigris enrollment, and project full enrollment closer to the end of the first quarter of 2025.” |
